Real‑time glucose race heats up
Real‑time glucose monitoring is reshaping chronic care — a new Chinese entrant has just signaled stronger competition in continuous analytics and remote monitoring. (openpr.com) At the same time, the U.S. AI diabetic‑retinopathy screening market is expanding with players like Eyenuk, Digital Diagnostics and Optomed scaling screening via AI, and CNET updated its recommendations on the best CGMs for consumers. (globenewswire.com) (cnet.com)
Huzhou Meiqi Medical Devices, based in Huzhou, Zhejiang, has surfaced as the Chinese entrant promoting an RGMS-series continuous glucose monitoring system sold under the RGMS-3O/RGMS branding. (en.mqcgm.com) Meiqi’s product pages state the system generates a dynamic glucose value every three minutes (about 480 readings per day), includes a mobile app for iOS/Android, and offers “guardian” / family sharing functions including WeChat-based remote viewing. (xmylcgm.com) Previous technical disclosures show MeiQi devices use Bluetooth Low Energy connectivity and Nordic Semiconductor nRF52-series SoCs in RGMS models, and earlier RGMS variants advertised up to 15 days of continuous monitoring per sensor. (nordicsemi.com) Market research firms project rapid expansion of China’s CGM market: one recent report values the market at roughly USD 505.13 million in 2023 and projects it to about USD 1.01 billion by 2032, underscoring why new domestic entrants are scaling device, analytics and remote‑monitoring offerings. (datainsightsmarket.com) In the U.S., analysts put the AI-driven diabetic‑retinopathy screening market at about USD 190.01 million in 2025 and forecast growth to roughly USD 881.74 million by 2033 (CAGR ~21.18%), naming firms such as Eyenuk, Digital Diagnostics and Optomed among active scale‑up players. (supplychaindigital.com) Those vendors have regulatory footprints: Eyenuk’s EyeArt received FDA 510(k) clearance in 2020 and later expanded camera compatibility, Digital Diagnostics (formerly IDx) gained De Novo authorization for IDx‑DR in 2018, and Optomed’s handheld Aurora with AEYE‑DS earned FDA clearance as a first‑of‑its‑kind handheld AI fundus camera. (eyenuk.com) Consumer guidance is shifting alongside that competition: CNET updated its “best continuous glucose monitors” roundup on Feb. 25, 2026, highlighting leading real‑time systems including Dexcom’s G7 and Abbott’s FreeStyle Libre 3 among top expert‑recommended options. (cnet.com)
